12 December 2017

Nottingham Doctors play pivotal role in new Endoscopic procedure for type 2 Diabetes

Nottingham's top diabetes, gastroenterology and metabolism experts are teaming together to investigate a ground-breaking new procedure.

Known as REVITA DMR, the 60-minute endoscopic procedure uses a balloon filled with hot water to alter how the upper intestine absorbs and processes dietary sugar.

As part of a new clinical trial, clinicians and researchers from the University of Nottingham, the NIHR Nottingham Biomedical Research Centre and the East Midlands Bariatric Metabolic Institute, are collaborating together to investigate the type 2 diabetes innovation, also referred to as duodenal mucosal resurfacing' (DMR), which is hoped may help restore the body's ability to regulate blood sugar.

Diabetes specialist Associate Professor Iskandar Idris is a leading researcher at the University of Nottingham. He comments: "This revolutionary procedure offers a method of potentially reversing diabetes progression and is an exciting alternative to conventional tablets or daily injections. My team is pleased to be working with our gastroenterology colleagues in this novel clinical trial."

Nottingham University Professor, consultant gastroenterologist at the NIHR Nottingham Biomedical Research Centre, and the Principal Investigator to this study, Krish Ragunath, adds: "I am excited to be part of such a ground-breaking clinical trial. The non-invasive procedure involves a catheter being swallowed and passed down the throat and stomach into the 'duodenum' where a balloon filled with hot water heats the cells, also known as 'thermal ablation'. Our hope is that patients will see a permanent reduction in their blood sugar."

Performed under general anaesthesia, the first patient is scheduled to undergo the incision-free and implant-free procedure at the end of November. NUH are currently recruiting further volunteers with type 2 diabetes, who live locally and in surrounding areas. For more information visit: http://revitatrial.com/.

To take part in the study, patients must be taking at least one oral diabetes medication. Those on injectable treatment (insulin or other diabetes injections) are not suitable for the Trial. If you're interested in finding out more information about the trial, please contact: Gayna Babington, NUH, at DiabetesResearchTrials@nuh.nhs.uk

NHS Nottingham University Hospitals
Cookie Disclaimer

Our website uses cookies to provide you with a better online experience. If you continue to use our site without changing your browser settings, we'll assume you are happy to receive cookies. Please read our Cookie policy for more information.